Loading...
XSHE
300702
Market cap1.04bUSD
Jul 10, Last price  
20.68CNY
1D
2.07%
1Q
-11.59%
IPO
59.88%
Name

Zhejiang Tianyu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300702 chart
P/E
51.51
P/S
2.35
EPS
0.40
Div Yield, %
0.25%
Shrs. gr., 5y
0.93%
Rev. gr., 5y
3.42%
Revenues
3.06b
+16.36%
723,249,900777,349,700840,085,3001,082,338,8231,188,282,8091,466,956,3812,110,595,6792,587,395,7102,545,009,5272,666,678,4712,527,270,1112,630,808,2423,061,135,393
Net income
140m
+149.78%
33,588,40024,139,80050,354,800122,337,693100,182,149163,661,962585,725,754667,060,800204,676,097-118,872,74127,359,26255,935,072139,712,806
CFO
474m
+37.41%
39,731,80080,438,31614,751,417164,739,55688,516,86978,572,392427,836,939622,180,52000-43,904,902344,638,322473,567,670
Dividend
Jun 06, 20250.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Tianyu Pharmaceutical Co., Ltd. is a global enterprise specializing in the entire lifecycle, from the innovation to the commercialization, of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). The company provides essential chemical building blocks for drugs targeting a diverse range of medical conditions, including cardiovascular disorders, diabetes, anti-atherosclerosis, blood coagulation issues, and asthma. In addition to its primary focus, the firm also delivers specialty chemicals and extends its services to include contract manufacturing (CMO) for other pharmaceutical entities. This Taizhou, China-based company was established in 1993.
IPO date
Sep 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT